Entera Bio (NASDAQ:ENTX) and MeiraGTx (NASDAQ:MGTX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, valuation, risk, analyst recommendations and dividends.
Risk & Volatility
Entera Bio has a beta of 2.38, suggesting that its share price is 138% more volatile than the S&P 500. Comparatively, MeiraGTx has a beta of 2.23, suggesting that its share price is 123% more volatile than the S&P 500.
This is a summary of current recommendations and price targets for Entera Bio and MeiraGTx, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Entera Bio currently has a consensus target price of $8.00, suggesting a potential upside of 325.53%. MeiraGTx has a consensus target price of $38.33, suggesting a potential upside of 86.81%. Given Entera Bio’s higher probable upside, research analysts plainly believe Entera Bio is more favorable than MeiraGTx.
Insider & Institutional Ownership
9.2% of Entera Bio shares are owned by institutional investors. Comparatively, 42.2% of MeiraGTx shares are owned by institutional investors. 17.4% of MeiraGTx shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Earnings & Valuation
This table compares Entera Bio and MeiraGTx’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Entera Bio||$500,000.00||42.97||-$10.30 million||N/A||N/A|
Entera Bio has higher revenue and earnings than MeiraGTx.
This table compares Entera Bio and MeiraGTx’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
MeiraGTx beats Entera Bio on 5 of the 9 factors compared between the two stocks.
About Entera Bio
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union bone fractures; and other platform modules. The company was founded in 2010 and is headquartered in Jerusalem, Israel. Entera Bio Ltd. operates as a subsidiary of D.N.A Biomedical Solutions Ltd.
MeiraGTx Holdings plc, a clinical-stage gene therapy company, focusing on developing treatments for patients living with serious diseases. The company develops various therapies for ocular diseases, including rare inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; neurodegenerative diseases, such as amyothrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. The company was founded in 2015 and is headquartered in New York, New York.
Receive News & Ratings for Entera Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entera Bio and related companies with MarketBeat.com's FREE daily email newsletter.